Y Intercept Hong Kong Ltd Buys New Position in Inovio Pharmaceuticals, Inc. $INO

Y Intercept Hong Kong Ltd purchased a new position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 42,171 shares of the biopharmaceutical company’s stock, valued at approximately $86,000. Y Intercept Hong Kong Ltd owned 0.12% of Inovio Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of INO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 5,894 shares in the last quarter. AQR Capital Management LLC bought a new stake in Inovio Pharmaceuticals during the first quarter valued at about $120,000. Nomura Holdings Inc. bought a new stake in Inovio Pharmaceuticals during the first quarter valued at about $28,000. Freedom Investment Management Inc. bought a new stake in Inovio Pharmaceuticals during the first quarter valued at about $31,000. Finally, Nuveen LLC purchased a new stake in Inovio Pharmaceuticals in the first quarter worth about $168,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Stock Performance

INO stock opened at $2.12 on Monday. The company’s fifty day moving average price is $2.45 and its 200-day moving average price is $2.04. Inovio Pharmaceuticals, Inc. has a one year low of $1.30 and a one year high of $5.60. The company has a market capitalization of $112.66 million, a PE ratio of -0.81 and a beta of 1.64.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.02. On average, research analysts predict that Inovio Pharmaceuticals, Inc. will post -4.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on INO. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Inovio Pharmaceuticals in a research report on Wednesday, October 8th. Citigroup restated a “market outperform” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, November 4th. HC Wainwright reiterated a “neutral” rating and issued a $3.00 price target on shares of Inovio Pharmaceuticals in a research report on Thursday, August 14th. Zacks Research cut shares of Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Finally, Wall Street Zen cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 16th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $8.80.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.